HK1213542A1 - 用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶 - Google Patents

用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶

Info

Publication number
HK1213542A1
HK1213542A1 HK16101289.0A HK16101289A HK1213542A1 HK 1213542 A1 HK1213542 A1 HK 1213542A1 HK 16101289 A HK16101289 A HK 16101289A HK 1213542 A1 HK1213542 A1 HK 1213542A1
Authority
HK
Hong Kong
Prior art keywords
treatment
hyperproliferative diseases
substituted indazol
pyrrolopyrimidines
useful
Prior art date
Application number
HK16101289.0A
Other languages
English (en)
Inventor
Ulrich Klar
Lars Wortmann
Georg Kettschau
Florian Phler
Philip Lienau
Kirstin Petersen
Andrea Hgebarth
Detlev Slzle
Keith Graham
Anja Richter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of HK1213542A1 publication Critical patent/HK1213542A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16101289.0A 2012-09-26 2016-02-04 用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶 HK1213542A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12186032 2012-09-26
EP13154193 2013-02-06
PCT/EP2013/069698 WO2014048869A1 (en) 2012-09-26 2013-09-23 Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases

Publications (1)

Publication Number Publication Date
HK1213542A1 true HK1213542A1 (zh) 2016-07-08

Family

ID=49231465

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101289.0A HK1213542A1 (zh) 2012-09-26 2016-02-04 用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶

Country Status (7)

Country Link
US (1) US20150252047A1 (zh)
EP (1) EP2900671A1 (zh)
JP (1) JP2015535833A (zh)
CN (1) CN104837841A (zh)
CA (1) CA2885783A1 (zh)
HK (1) HK1213542A1 (zh)
WO (1) WO2014048869A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470931B (zh) 2012-05-21 2016-10-26 拜耳医药股份有限公司 取代的苯并噻吩并嘧啶
US9540392B2 (en) 2012-05-21 2017-01-10 Bayer Pharma Aktiengesellschaft Thienopyrimidines
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014135480A1 (en) 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
AU2015257917C1 (en) * 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP6427599B2 (ja) 2014-05-19 2018-11-21 チャンスー ヘンルイ メディシン カンパニー，リミテッド チロシンキナーゼ阻害剤としての置換エチニルヘテロ二環式化合物
WO2016172010A1 (en) 2015-04-20 2016-10-27 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
CA3034010A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN110903286B (zh) * 2019-12-16 2021-09-24 沈阳药科大学 4,6-双取代吡啶[3,2-d]嘧啶类化合物及其制备和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2265739B1 (zh) 1974-03-29 1976-12-17 Ugine Kuhlmann
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
MX9709867A (es) 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AR050365A1 (es) 2004-08-02 2006-10-18 Osi Pharm Inc Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
CN101052629A (zh) * 2004-08-02 2007-10-10 Osi制药公司 芳基－氨基取代的吡咯并嘧啶多激酶抑制化合物
JP5255559B2 (ja) 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2011013656A1 (ja) * 2009-07-28 2011-02-03 第一三共株式会社 ピロロ［２，３－ｄ］ピリミジン誘導体
RU2012125070A (ru) * 2009-11-18 2013-12-27 Плексксикон, Инк. Соединения и способы модулирования киназы и показания к их применению
US8580803B2 (en) * 2009-12-30 2013-11-12 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds

Also Published As

Publication number Publication date
EP2900671A1 (en) 2015-08-05
CA2885783A1 (en) 2014-04-03
US20150252047A1 (en) 2015-09-10
CN104837841A (zh) 2015-08-12
WO2014048869A1 (en) 2014-04-03
JP2015535833A (ja) 2015-12-17

Similar Documents

Publication Publication Date Title
IL274771A (en) Use of pyrazolopyrimidine derivatives for the treatment of PI3Kδ associated disorders
HK1213542A1 (zh) 用於治療過度增殖性疾病的取代的吲唑-吡咯並嘧啶
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HRP20180659T1 (hr) Disperzija amorfne krutine, namijenjena upotrebi u liječenju raka na mozgu
HRP20180670T1 (hr) Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
HK1212340A1 (zh) 用於治療過度增殖性障礙的取代的吲唑-吡咯並嘧啶
GB201506561D0 (en) Treatment of amblyopia
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
HK1211213A1 (zh) 涉及粘液素的疾病治療
EP3013824B8 (en) Carboline compounds usable in the treatment of neurodegenerative diseases
EP2825194A4 (en) USE OF ANTITHROMBINE IN THE TREATMENT OF PRE-ECLAMPSIA
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
IL239078A0 (en) Protein for use in the treatment of eye diseases